title: MET expression is associated with disease-specific survival in breast cancer patients in the neoadjuvant setting.
abstract: MET and RON receptor tyrosine kinases play an important role in tumor progression. The aim of this study was to determine the predictive or prognostic impact of MET and RON in breast cancer patients treated with neoadjuvant chemotherapy (NAC). Immunohistochemical analyses were performed to retrospectively examine the predictive or prognostic impact of MET and RON expression in 129 breast cancer patients treated with NAC followed by definitive surgical resection. MET-positive tumors were detected in 89 patients (68.9%) and RON-positive tumors in 94 patients (72.9%). Survival analysis showed that MET expression was correlated with longer disease-specific survival (DSS; P=0.016), whereas RON expression was not associated with survival rates. MET expression was a significant factor for DSS in the non-pCR group in subgroup analysis (P=0.024) and a marginal significant independent prognostic factor for DSS in multivariate analysis. The MET-positive group had higher pCR than the MET-negative group but the difference was not statistically significant (P=0.266). MET expression is a prognostic factor for DSS in breast cancer patients receiving NAC and may provide additional prognostic information in patients not achieving a pCR.
authors.affiliation: Department of Pathology, Ajou University School of Medicine, Suwon, Republic of Korea.
authors.forename: Young Wha
authors.initials: YW
authors.lastname: Koh
authors.affiliation: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Lee
authors.affiliation: Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Ahn
authors.affiliation: Division of Breast and Endocrine Surgery, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Jong Won
authors.initials: JW
authors.lastname: Lee
authors.affiliation: Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea. Electronic address: gygong@amc.seoul.kr.
authors.forename: Gyungyub
authors.initials: G
authors.lastname: Gong
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met; C080835:RON protein; D020794:Receptor Protein-Tyrosine Kinases
keywords: Breast cancer; MET; Neoadjuvant chemotherapy; Prognosis; RON